Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of chimeric antigen receptor (CAR)-T cell therapy, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Sadelain describes the progress CAR T-cell therapy has made, and suggests that we should aim to improve our current understanding of CAR-T mediated toxicities.